Supplement Dupilumab in prurigo nodularis: 52-week effectiveness and safety from the prospective multicenter BioDay registry

Description

Supplemental Material: Supplement - Extended methods Supplementary Table I. Baseline characteristics Supplementary Table II. Effectiveness outcomes during 52 weeks of treatment with dupilumab for prurigo nodularis Supplementary Figure 1. Effectiveness outcomes IGA PN-S, PP-NRS, DLQI, and NRS sleep deprivation over time Supplementary Figure 2. Effectiveness of dupilumab in patients with and without comorbid atopic dermatitis Supplementary Table III Effectiveness outcomes differentiated by history of atopic dermatitis, history of any atopic comorbidity, and sex Supplementary Table IV. Adverse events reported during follow-up Supplementary Table V. Serious Adverse Events reported during follow-up

Institutions

• University Medical Center Utrecht

  Utrecht, Utrecht

Categories

Licence